Sildenafil orally-dissolving film - NAL PHarma

Drug Profile

Sildenafil orally-dissolving film - NAL PHarma

Alternative Names: NAL-8238; Sildenafil ODF - NAL Pharma

Latest Information Update: 23 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NAL Pharma
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Clinical Phase Unknown Erectile dysfunction

Most Recent Events

  • 23 Mar 2016 Sildenafil orally-dissolving film is available for licensing in World as of 23 Mar 2016.
  • 23 Mar 2016 Clinical trials in Erectile dysfunction in Hong Kong (Sublingual)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top